Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exemestane plus Everolimus maintenance in HR+ metastatic breast cancer
NCT02025712Phase 2Unknown
- Sponsor
- Organisation for Oncology and Translational Research
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in breast cancer, sponsored by Organisation for Oncology and Translational Research. Primary endpoint: Progression Free Survival up to 8 months. Status: unknown.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02025712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02025712.